BiVictriX Therapeutics (LON:BVX) Stock Price Up 17.6% – Time to Buy?

BiVictriX Therapeutics Plc (LON:BVX)’s share price shot up 17.6% on Wednesday . The company traded as high as GBX 10 ($0.13) and last traded at GBX 10 ($0.13). 1,538,020 shares traded hands during trading, an increase of 1,320% from the average session volume of 108,326 shares. The stock had previously closed at GBX 8.50 ($0.11).

BiVictriX Therapeutics Price Performance

The company has a current ratio of 4.40, a quick ratio of 7.49 and a debt-to-equity ratio of 8.81. The business’s fifty day moving average is GBX 9.58 and its 200 day moving average is GBX 10.90. The company has a market cap of £8.25 million, a P/E ratio of -250.00 and a beta of -0.73.

Insiders Place Their Bets

In other news, insider Robert Edward Hawkins purchased 20,000 shares of the business’s stock in a transaction on Friday, August 30th. The shares were acquired at an average price of GBX 7 ($0.09) per share, with a total value of £1,400 ($1,801.57). Corporate insiders own 42.56% of the company’s stock.

BiVictriX Therapeutics Company Profile

BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia, as well as develops BVX002 and BVX003 for various blood cancers and solid tumours.